Skip to main content
Clinical Trials/NCT05157932
NCT05157932Active, not recruitingNot Applicable

An Evaluation of the Talk Test as an Effective and Safe Approach for Exercise Prescription for Home-Based Cardiac Rehabilitation: A Pilot RCT

Ottawa Heart Institute Research Corporation1 site in 1 country40 target enrollmentStarted: July 8, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
40
Locations
1
Primary Endpoint
Exercise capacity

Study Overview

Brief Summary

The objectives of this pilot RCT are to examine if the Talk Test is an effective and safe tool as compared with CPET for exercise prescription in patients who have undergone CABG or PCI and enrolled in a home-based CR program with virtual exercise training monitoring.

Detailed Description

The Talk Test has been shown to be a valid, practical and inexpensive tool for guiding exercise training in patients with CAD. The general premise of the Talk Test is that exercising at or above the ventilatory threshold or lactate threshold does not allow comfortable, conversational speech and thus serves as a means of estimating the cut point between moderate and vigorous intensity exercise. The Talk Test can be used to produce exercise intensities (64 to 95% HR peak i.e. moderate-to-vigorous intensity exercise) within accepted Canadian Association of Cardiovascular Prevention and Rehabilitation (CACPR) guidelines for exercise training, to avoid exertional ischemia, and has been shown to be consistent across various modes of exercise (i.e. walking, jogging, cycling, elliptical trainer and stair stepper).

There is a critical need to evaluate the effectiveness and safety of using the Talk Test as the principal method of exercise prescription in patients with CAD who have undergone CABG or PCI when compared to standard care CPET. Such a trial has wide-scale appeal for CR programs across Canada and beyond. It will directly and positively impact patient care by reducing the need for in-person interactions for CPET, of paramount importance during COVID-19 outbreaks, between patients and CR staff, thus reducing COVID-19 infection risk and concerns of contracting the virus.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
40 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •recently underwent PCI or CABG (at least 4 weeks but less than 12 weeks post-event or procedure);
  • •able to perform a CPET;
  • •at least 40 years of age;
  • •access to MyChart; and,
  • •access to email and the internet
  • •access to a cellphone with broadband internet (4G, LTE, 5G).

Exclusion Criteria

  • •currently participating in a virtual or on-site CR program;
  • •ventricular ejection fraction ≤45%;
  • •unstable angina or established diagnosis of chronic obstructive pulmonary disease, severe mitral or aortic stenosis, or hypertrophic obstructive cardiomyopathy;
  • •unable to return for 12-week follow-up visits.

Arms & Interventions

Talk Test

Experimental

Virtual Cardiac Rehab + Exercise prescription based on the Talk test.

Intervention: Talk test prescription (Behavioral)

Cardiopulmonary Exercise Test

Experimental

Virtual Cardiac Rehab + Exercise prescription based on the CPET results.

Intervention: CPET prescription (Behavioral)

Outcomes

Primary Outcomes

Exercise capacity

Time Frame: from baseline to follow-up at week 12

will be measured by the Incremental Shuttle Walk Test.

Secondary Outcomes

  • Cardiovascular health indicators - Plasma glucose average(from baseline to follow-up at week 12)
  • Cardiovascular health indicators - Cholesterol LDL(from baseline to follow-up at week 12)
  • Cardiovascular health indicators - Cholesterol HDL(from baseline to follow-up at week 12)
  • Cardiovascular health indicators - Plasma glucose(from baseline to follow-up at week 12)
  • Cardiovascular health indicators - Lipid profile(from baseline to follow-up at week 12)
  • Cardiac Rehab safety(from baseline to follow-up at week 12)
  • VO2peak(at baseline)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

An Evaluation of the Talk Test for... | Clinical Trial